BS_KN92S7YQ
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 47.88
- os_event
- false
- age_years
- 13.288
- sex
- M
- race
- White
- new_clusters
- C6
- umap1_2d
- 4.281765366
- umap2_2d
- 6.760439204
- umap1_3d
- 2.624551707
- umap2_3d
- -0.069399394
- umap3_3d
- -3.833078959
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INFLAMMATORY_RESPONSE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.380
- COMPLEMENT+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
- ALLOGRAFT_REJECTION+0.290
- COAGULATION+0.290
- INTERFERON_ALPHA_RESPONSE+0.260
- KRAS_SIGNALING_UP+0.230
- HYPOXIA+0.210
- INTERFERON_GAMMA_RESPONSE+0.200
Top 10 suppressed
- MYC_TARGETS_V2-0.680
- MYC_TARGETS_V1-0.650
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.570
- OXIDATIVE_PHOSPHORYLATION-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.410
- DNA_REPAIR-0.350
- MITOTIC_SPINDLE-0.310
- MTORC1_SIGNALING-0.310
- WNT_BETA_CATENIN_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2283 | Med | Medulloblastoma | 0.919 |
| 2 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.881 |
| 3 | TCGA-F7-A50G-01A-11R-A266-07 | — | — | 0.873 |
| 4 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.872 |
| 5 | BS_NZ71XCG3 | Med | Medulloblastoma | 0.871 |
| 6 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.871 |
| 7 | TCGA-69-8254-01A-11R-2287-07 | — | cohortA1 | 0.866 |
| 8 | BS_NQB91P48 | pilocytic astrocytoma | — | 0.865 |
| 9 | BS_0WVJYM9R | pilocytic astrocytoma | — | 0.862 |
| 10 | MDT-AP-2888 | Med | Medulloblastoma | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.120 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |